N-morpholinoacetyl-L-phenylalanine | 119357-71-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-morpholinoacetyl-L-phenylalanine
• 英文别名: (2S)-2-[(2-morpholin-4-ylacetyl)amino]-3-phenylpropanoic acid
• CAS: 119357-71-0
• 化学式: C₁₅H₂₀N₂O₄
• 分子量: 292.335
• InChiKey: GHZYYEPUTNTVMI-ZDUSSCGKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.5
• 重原子数：
  21
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  78.9
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  N-morpholinoacetyl-L-phenylalanine 、 (2S,4S,5S)-5-[N-(t-butoxycarbonyl)-3-(4-thiazolyl)-L-alanyl]amino-6-cyclohexyl-4-hydroxy-2-(1-hydroxy-1-methylethyl)-N-methylhexanamide 、 氰基磷酸二乙酯 在 三乙胺 作用下， 以77%的产率得到(2S,4S,5S)-5-{N-[N-Morpholinoacetyl-L-phenylalanyl]-3-(4-thiazolyl)-L-alanyl}amino-6-cyclohexyl-4-hydroxy-2-(1-hydroxy-1-methylethyl)-N-methylhexanamide
  参考文献：
  名称：

  Renin-inhibitory oligopeptides, their preparation and use

  摘要：

  式(I)的化合物: A是碳-碳键或C.sub.1 -C.sub.3烷基; B是亚胺基或C.sub.1 -C.sub.2烷基; R.sup.1是C.sub.1 -C.sub.4烷基，C.sub.1 -C.sub.4烷氧基，杂环或可选择取代的氨基; R.sup.2是可选择取代的苯基或可选择取代的萘基; R.sup.3是噻唑基，异噁唑基或咪唑基; R.sup.4是异丙基或环己基; R.sup.5和R.sup.6是C.sub.1 -C.sub.4烷基，或者与其连接的碳原子一起是C.sub.3 -C.sub.7环烷基; R.sup.7是氢，可选择取代的C.sub.1 -C.sub.6烷基; R.sup.8是氢或C.sub.1 -C.sub.4烷基。这些化合物具有抑制肾素的作用，因此具有降压活性。本发明还提供了一种治疗或预防由于肾素-血管紧张素系统功能障碍引起的高血压的方法。

  公开号：

  US05364844A1
• 作为产物：
  描述：

  ethyl N-morpholinoacetyl-L-phenylalanate 在 盐酸 、 sodium hydroxide 作用下， 以 甲醇 为溶剂， 生成 N-morpholinoacetyl-L-phenylalanine
  参考文献：
  名称：

  New renin-inhibitory oligopeptides, their preparation and their use

  摘要：

  式(I)的寡肽：##STR1##其中R.sup.1 -R.sup.5是各种有机基团，A代表式--NH--或--(CH.sub.2).sub.n --的基团，其中n表示1到3之间的整数，具有抑制肾素活性，并且特别适合口服。它们可以通过使用传统的肽合成反应将它们的组成氨基酸或较低寡肽进行缩合来制备。

  公开号：

  US05378690A1

文献信息

• New renin-inhibitory oligopeptides, their preparaton and their use
  申请人：Sankyo Company Limited

  公开号：EP0274259A2

  公开（公告）日：1988-07-13

  New renin-inhibitory oligopeptides, their preparaton and their use. Oligopeptides of formula (I): where R1 -R5 are various organic groups, and A represents a group of formula -NH-or -(CH2)n-, in which n represents an integer of from 1 to 3, have renin-inhibitory activity and are particularly suitable for oral administration. They may be prepared by condensing their component amino acids or lower oligopeptides using conventional peptide synthesis reactions.

  新的抑制肾素的低聚肽及其制备方法和用途。式(I)的寡肽： 其中 R1 -R5 是各种有机基团，A 代表式-NH-或-(CH2)n-的基团，其中 n 代表 1 至 3 的整数，具有肾素抑制活性，特别适合口服。它们可以通过传统的肽合成反应缩合其氨基酸组分或低级寡肽来制备。
• Renin inhibitors, processes for preparing them, methods for using them, and compositions containing them
  申请人：WARNER-LAMBERT COMPANY

  公开号：EP0314060A2

  公开（公告）日：1989-05-03

  The invention concerns novel renin-inhibitory peptides which are useful for treating renin-associated hypertension, congestive heart failure, and hyperaldosteronism. Processes for preparing the peptides, novel intermediates useful in the preparation thereof, compositions containing them, and methods of using them are included. Also included is a diagnostic method which uses the compounds to determine the presence of renin-associated hypertension, congestive heart failure, or hyperaldosteronism.

  本发明涉及新型肾素抑制肽，可用于治疗肾素相关性高血压、充血性心力衰竭和高醛固酮症。本发明包括制备这些肽的工艺、用于制备这些肽的新型中间体、含有这些肽的组合物以及使用这些肽的方法。还包括一种诊断方法，该方法使用这些化合物来确定是否存在肾素相关性高血压、充血性心力衰竭或高醛固酮症。
• Renin inhibitory oligopeptides, their preparation and use
  申请人：Sankyo Company Limited

  公开号：EP0326364A2

  公开（公告）日：1989-08-02

  Compounds of formula (I): [in which: A is a carbon-carbon bond or C1 - C3 alkylene; B is imino group or C1- C2 alkylene; R1 is C1- C4 alkyl, Ci - C4 alkoxy, heterocyclic or optionally substituted amino; R2 is optionally substituted phenyl or optionally substituted naphthyl; R3 is thiazolyl, isoxazolyl or imidazolyl; R4 is isopropyl or cyclohexyl; R5 and R6 are Ci - C4 alkyl, or, together with the carbon atom to which they are attached, C3- C7 cycloalkyl; R7 is hydrogen or optionally substituted C1- C6 alkyl; and R8 is hydrogen or Ci - C4 alkyl] have renin-inhibitory and, hence, hypotensive activities and are of value in the diagnosis and treatment of hypertension induced by failures in the renin-angiotensin system. They may be prepared by reacting together appropriate amino acids, lower oligopeptides or derivatives thereof.

  式(I)化合物： 其中A 是碳-碳键或 C1 - C3 亚烷基；B 是亚氨基或 C1 - C2 亚烷基；R1 是 C1 - C4 烷基、Ci - C4 烷氧基、杂环或任选取代的氨基；R2 是任选取代的苯基或任选取代的萘基；R3 是噻唑基、异噁唑基或咪唑基；R4 是异丙基或环己基；R5 和 R6 是 Ci - C4 烷基，或与所连接的碳原子一起是 C3 - C7 环烷基；R7 是氢或任选取代的 C1 - C6 烷基；以及 R8 是氢或 Ci - C4 烷基]。 具有肾素抑制活性，因此具有降血压活性，在诊断和治疗由肾素-血管紧张素系统故障引起的高血压方面具有价值。它们可通过将适当的氨基酸、低级寡肽或其衍生物反应在一起而制备。
• Compounds for proteasome enzyme inhibition
  申请人：Proteolix, Inc.

  公开号：EP2030981A1

  公开（公告）日：2009-03-04

  Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-termmal nucleophile (Nin) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by she compounds described. For example, the chymotrypsinlike activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation.

  包括含杂原子的三元环的肽基化合物能有效地、选择性地抑制 N-三卤代亲核物（Nin）水解酶的特定活性。具有多种活性的 Ntn 的活性可受到所述化合物的不同抑制。例如，本发明化合物可选择性地抑制 20S 蛋白酶体的糜蛋白酶样活性。肽基化合物包括环氧化物或氮丙啶，以及 N 端的官能化。除其他治疗作用外，肽基化合物还具有抗炎和抑制细胞增殖的作用。
• RENIN INHIBITORS, PROCESSES FOR PREPARING THEM, METHODS FOR USING THEM, AND COMPOSITIONS CONTAINING THEM
  申请人：WARNER-LAMBERT COMPANY

  公开号：EP0389535A1

  公开（公告）日：1990-10-03